Cingulate Future Growth
Future criteria checks 3/6
Cingulate is forecast to grow earnings and revenue by 65.6% and 63.4% per annum respectively while EPS is expected to grow by 70.6% per annum.
Key information
65.6%
Earnings growth rate
70.6%
EPS growth rate
| Pharmaceuticals earnings growth | 23.6% |
| Revenue growth rate | 63.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 04 Sep 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 13 | 1 | N/A | N/A | 2 |
| 12/31/2025 | N/A | -13 | N/A | -14 | 3 |
| 12/31/2024 | N/A | -13 | N/A | -12 | 3 |
| 6/30/2024 | N/A | -19 | -18 | -17 | N/A |
| 3/31/2024 | N/A | -23 | -20 | -20 | N/A |
| 12/31/2023 | N/A | -24 | -15 | -15 | N/A |
| 9/30/2023 | N/A | -21 | -17 | -17 | N/A |
| 6/30/2023 | N/A | -19 | -16 | -16 | N/A |
| 3/31/2023 | N/A | -17 | -16 | -16 | N/A |
| 12/31/2022 | N/A | -18 | -16 | -16 | N/A |
| 9/30/2022 | N/A | -16 | -17 | -16 | N/A |
| 6/30/2022 | N/A | -27 | -16 | -15 | N/A |
| 3/31/2022 | N/A | -24 | -13 | -13 | N/A |
| 12/31/2021 | N/A | -21 | -11 | -10 | N/A |
| 9/30/2021 | N/A | -19 | -8 | -8 | N/A |
| 6/30/2021 | N/A | -5 | -7 | -7 | N/A |
| 3/31/2021 | N/A | -6 | -7 | -7 | N/A |
| 12/31/2020 | N/A | -7 | -7 | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CING is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: CING is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CING is expected to become profitable in the next 3 years.
Revenue vs Market: CING is forecast to have no revenue next year.
High Growth Revenue: CING is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CING's Return on Equity is forecast to be high in 3 years time